[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BE2014C055I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C055I2
BE2014C055I2 BE2014C055C BE2014C055C BE2014C055I2 BE 2014C055 I2 BE2014C055 I2 BE 2014C055I2 BE 2014C055 C BE2014C055 C BE 2014C055C BE 2014C055 C BE2014C055 C BE 2014C055C BE 2014C055 I2 BE2014C055 I2 BE 2014C055I2
Authority
BE
Belgium
Application number
BE2014C055C
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34397024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C055(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of BE2014C055I2 publication Critical patent/BE2014C055I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
BE2014C055C 2003-09-26 2014-09-10 BE2014C055I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50618103P 2003-09-26 2003-09-26
US53537704P 2004-01-09 2004-01-09
US57738404P 2004-06-04 2004-06-04
EP04789057A EP1673085B1 (fr) 2003-09-26 2004-09-24 Modulateurs de c-met et procedes d'utilisation

Publications (1)

Publication Number Publication Date
BE2014C055I2 true BE2014C055I2 (fr) 2023-12-14

Family

ID=34397024

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C055C BE2014C055I2 (fr) 2003-09-26 2014-09-10

Country Status (20)

Country Link
US (14) US9174947B2 (fr)
EP (9) EP2392564B1 (fr)
JP (14) JP4638436B2 (fr)
AT (3) ATE532782T1 (fr)
AU (3) AU2004275842B2 (fr)
BE (1) BE2014C055I2 (fr)
CA (2) CA2537812C (fr)
CY (3) CY1111956T1 (fr)
DK (4) DK2392565T3 (fr)
ES (6) ES2371383T3 (fr)
FR (1) FR14C0067I2 (fr)
HK (5) HK1141799A1 (fr)
HR (4) HRP20110707T1 (fr)
HU (1) HUS1400052I1 (fr)
LU (1) LU92508I2 (fr)
NL (1) NL300678I2 (fr)
PL (3) PL2210607T3 (fr)
PT (2) PT2213661E (fr)
SI (4) SI2213661T1 (fr)
WO (1) WO2005030140A2 (fr)

Families Citing this family (263)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2282299T3 (es) 2000-10-20 2007-10-16 EISAI R&D MANAGEMENT CO., LTD. Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
ES2279441T3 (es) 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
CA2537812C (fr) * 2003-09-26 2013-01-22 Exelixis, Inc. Modulateurs de c-met et procede d'utilisation
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
AU2004291147A1 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
WO2005073224A2 (fr) * 2004-01-23 2005-08-11 Amgen Inc Composes et methodes d'utilisation de ces derniers
TW200538097A (en) * 2004-02-27 2005-12-01 Eisai Co Ltd Novel pyridine derivative and pyrimidine derivative
WO2005096784A2 (fr) 2004-04-08 2005-10-20 Targegen, Inc. Inhibiteurs benzotriazine de kinases
RU2468021C2 (ru) 2004-08-25 2012-11-27 Таргеджен, Инк. Гетероциклические соединения и их применение
CA2579810C (fr) 2004-09-17 2012-01-24 Eisai R&D Management Co., Ltd. Compositions pharmaceutiques stables a base de 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxyquinoline-6-carboxamide
TW200626139A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CA2580787A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et utilisation de ceux-ci comme agents therapeutiques
CA2580845A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
TW200624427A (en) 2004-09-20 2006-07-16 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
EP2266569A3 (fr) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
US8153643B2 (en) 2004-10-12 2012-04-10 Astrazeneca Ab Quinazoline derivatives
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
US7576090B2 (en) * 2004-12-27 2009-08-18 4Sc Ag Benzazole analogues and uses thereof
EP1674466A1 (fr) * 2004-12-27 2006-06-28 4Sc Ag Derives benzazoles 2,5- et 2-6-disubstitues utiles comme des inhibiteurs de la proteine kinase
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
BRPI0610322B8 (pt) * 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
MX2007015056A (es) * 2005-06-02 2008-03-11 Galaxy Biotech Llc Metodos para el tratamiento de tumores de cerebro con anticuerpos.
EP2029138A1 (fr) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
WO2007015578A1 (fr) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. Procédé d’analyse de l’effet d’un inhibiteur de vascularisation
CN101198590B (zh) 2005-08-24 2012-05-09 卫材R&D管理有限公司 吡啶衍生物及嘧啶衍生物（3）
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
WO2007033196A1 (fr) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Inhibiteurs de la kinase de met
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
CA2636242A1 (fr) * 2006-01-30 2008-05-29 Array Biopharma, Inc. Composes heterobicycliques de thiophene et leurs methodes d'utilisation
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
KR20080110783A (ko) 2006-03-07 2008-12-19 어레이 바이오파마 인크. 헤테로바이시클릭 피라졸 화합물 및 사용 방법
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
PL2010528T3 (pl) 2006-04-19 2018-03-30 Novartis Ag 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
JP5190361B2 (ja) 2006-05-18 2013-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 甲状腺癌に対する抗腫瘍剤
BRPI0711588A2 (pt) 2006-05-19 2011-11-16 Abbott Lab derivados alcano azabicìclico substituìdo com bicicloeterociclo fundido
WO2008035209A2 (fr) * 2006-05-30 2008-03-27 Methylgene Inc. Inhibiteurs de l'activité tyrosine kinase
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
EP2057164A1 (fr) 2006-08-07 2009-05-13 Incyte Corporation Utilisation de triazolotriazines en tant qu'inhibiteurs des kinases
AU2007288793B2 (en) 2006-08-23 2012-04-19 Eisai R & D Management Co., Ltd. Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
CA2669111C (fr) 2006-10-23 2016-04-12 Cephalon, Inc. Derives bicycliques fusionnes de 2,4-diaminopyrimidine utilises comme inhibiteurs de alk et c-met
US20100016307A1 (en) * 2006-10-27 2010-01-21 Toshihiro Hamajima Novel compounds
CN103288833B (zh) 2006-11-22 2018-01-12 因塞特控股公司 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶
AU2007338795B2 (en) * 2006-12-20 2012-07-19 Amgen Inc. Substituted heterocycles and methods of use
EP2125781A2 (fr) * 2006-12-20 2009-12-02 Amgen Inc. Hétérocycles substitués et leurs méthodes d'utilisation
US8551995B2 (en) * 2007-01-19 2013-10-08 Xcovery Holding Company, Llc Kinase inhibitor compounds
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
CN101754965B (zh) * 2007-05-21 2014-03-19 诺华股份有限公司 Csf-1r抑制剂、组合物及使用方法
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
PE20090595A1 (es) 2007-08-15 2009-06-06 Glaxo Group Ltd Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1
DK2183254T3 (en) 2007-08-29 2017-09-11 Methylgene Inc INHIBITORS OF PROTEINTYROSINKINASE ACTIVITY
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
EP2235001B1 (fr) 2008-01-23 2014-12-24 Bristol-Myers Squibb Company Procédé de préparation de composés de pyridinone
HUE032873T2 (en) 2008-03-17 2017-11-28 Ambit Biosciences Corp 1- (3- (6,7-Dimethoxyquinazolin-4-yloxy) phenyl) -3- (5- (1,1,1-trifluoro-2-methylpropan-2-yl) isoxazol-3-yl) urea as RAF kinase inhibitor for the treatment of cancer
BRPI0911679B8 (pt) 2008-04-10 2021-05-25 Taiho Pharmaceutical Co Ltd composto aciltioureia ou um sal do mesmo, uso do dito composto para tratar câncer, bem como agente farmacêutico, agente antitumoral e composição farmacêutica compreendendo dito composto
CA2718538A1 (fr) * 2008-04-16 2009-10-22 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Derives de quinolines utilises comme inhibiteurs des kinases axl
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
CL2009001250A1 (es) 2008-05-21 2010-02-05 Sal del acido dihidroclorico y dibencensulfonico de 2-fluoro-n-metil-4-[7-(quinolin-6-ilmetil)imidazol[1,2-b][1,2,4]1,2,4]triazin-2-il]benzamida; compuestos intermediarios; procesos de preparacion; composicion farmaceutica; y uso para tratar cancer, aterosclerosis, fibrosis pulmonar, enfermedad renal, entre otras.
AU2009271003A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
EP2303841A1 (fr) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Composés inhibiteurs de l oxindolyle
JP5640006B2 (ja) 2008-07-14 2014-12-10 ギリアード サイエンシーズ， インコーポレイテッド ヒストン脱アセチル化酵素および／またはサイクリン依存性キナーゼの縮合複素環式阻害剤
EP2149565A1 (fr) * 2008-07-24 2010-02-03 Bayer Schering Pharma AG Dérivés de chinazoline substitués par du sulfonamide en tant que modulateurs d'immunité pour le traitement de inflammations et allergies
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
AR075084A1 (es) * 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
EP2532657B9 (fr) * 2008-10-14 2017-04-19 Sunshine Lake Pharma Co., Ltd. Composés et procédés d'utilisation
WO2010051373A1 (fr) * 2008-10-29 2010-05-06 Deciphera Pharmaceuticals, Llc Amides de cyclopropane et analogues présentant des activités anticancéreuses et antiprolifératives
TW201022258A (en) * 2008-11-13 2010-06-16 Exelixis Inc Methods of preparing quinoline derivatives
CN102239148A (zh) * 2008-12-04 2011-11-09 埃克塞里艾克西斯公司 喹啉衍生物的制备方法
DE102009003975A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
KR20200137052A (ko) * 2009-01-16 2020-12-08 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
EP2210891A1 (fr) * 2009-01-26 2010-07-28 Domain Therapeutics Nouveaux ligands du récepteur de l'adénosine et leurs utilisations
MX2011009926A (es) * 2009-03-21 2012-01-27 Ning Xi Derivados de amino esteres, sales de los mismos, y metodos de uso.
EP2438051A1 (fr) 2009-06-05 2012-04-11 Pfizer Inc. Derives de l-(piperidin-4-yl)-pyrazole utilises en tant que modulateurs du gpr 119
EP2440517B1 (fr) 2009-06-08 2014-03-26 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline hdac inhibiteur composés
EP2440519A1 (fr) 2009-06-08 2012-04-18 Gilead Sciences, Inc. Composés inhibiteurs d'hdac à base d'alkanoylamino benzamide aniline
WO2011009095A1 (fr) 2009-07-17 2011-01-20 Exelixis, Inc. Formes cristallines du n‑[3‑fluoro-4-({méthyloxy)-7-[(3-morpholin-4-yl- propyl)oxy]quinoléin-4-yl}oxy)phényl]-n'-(4-fluorophényl)cyclopropane- 1,1-dicarboxamide
UA108618C2 (uk) * 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CN102030705B (zh) * 2009-09-30 2012-12-19 上海睿智化学研究有限公司 7-苄氧基-6-甲氧基-4-羟基喹啉的合成方法
EP2311809A1 (fr) * 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
WO2011056740A1 (fr) * 2009-11-03 2011-05-12 Glaxosmithkline Llc Composés de quinazoline
AU2010322796A1 (en) * 2009-11-27 2012-07-12 Proteologics, Ltd. Quinazolin-4(3A)-one derivatives and methods of use thereof
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
CN102086211B (zh) * 2009-12-08 2013-09-11 广东东阳光药业有限公司 作为蛋白激酶抑制剂的芳杂环化合物
CA2788398C (fr) 2010-02-03 2018-02-27 Incyte Corporation Imidazo[1,2-b][1,2,4]triazines en tant qu'inhibiteurs de c-met
KR20130038206A (ko) * 2010-03-12 2013-04-17 엑셀리시스, 인코포레이티드 Ｎ-〔3-플루오로-4-(｛6-（메틸옥시）-7-〔（3-모폴린-4-일프로필）옥시〕-퀴놀린-4-일｝옥시）페닐〕-ｎ’-（4-플루오로페닐）사이클로프로판-1,1-디카복사미드의 수화된 결정형 형태
EP2553641A4 (fr) * 2010-03-26 2015-01-07 EastNets Système informatique de paiement mobile et procédé
CN102212062B (zh) * 2010-04-02 2015-04-29 广东东阳光药业有限公司 氨基酯类衍生物及其盐和使用方法
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (fr) 2010-04-23 2015-10-28 Cytokinetics, Inc. Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation
WO2011139891A1 (fr) 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Analogues et amides de pyridone présentant des activités anticancéreuse et antiproliférative
NZ604306A (en) 2010-05-17 2015-02-27 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
CA2802644C (fr) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Agent anticancereux utilisant des composes ayant un effet inhibiteur de kinase en combinaison
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
EP2593091A1 (fr) 2010-07-16 2013-05-22 Exelixis, Inc. Compositions pharmaceutiques modulatrices de c-met
PT2593090T (pt) * 2010-07-16 2021-11-04 Exelixis Inc Composições farmacêuticas moduladoras de c-met
EP2423208A1 (fr) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Composants actifs pharmaceutiquement en tant qu'inhibiteurs Axl
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
JP2013537918A (ja) * 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
JP6158705B2 (ja) * 2010-09-27 2017-07-05 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
JP2013540759A (ja) * 2010-09-27 2013-11-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
EP2643001A4 (fr) * 2010-11-22 2014-02-19 Glaxosmithkline Ip Dev Ltd Procédé de traitement du cancer
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
KR102030447B1 (ko) 2011-02-10 2019-11-08 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのアミノキノリン
US20120252840A1 (en) * 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
MX2013012695A (es) * 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
WO2012166899A2 (fr) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
US9309237B2 (en) 2011-09-06 2016-04-12 New York Blood Center, Inc. HIV inhibitors
CN102408411B (zh) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
ES2639093T3 (es) * 2011-09-22 2017-10-25 Exelixis, Inc. Procedimiento para el tratamiento de la osteoporosis
AU2012325768B2 (en) * 2011-10-20 2017-08-10 Exelixis, Inc. Process for preparing quinoline derivatives
US8843421B2 (en) 2011-11-01 2014-09-23 Accenture Global Services Limited Identification of entities likely to engage in a behavior
MX2014005458A (es) 2011-11-08 2015-04-16 Exelixis Inc Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer.
JP2015505360A (ja) 2011-11-08 2015-02-19 エクセリクシス， インク． 癌治療を定量化する方法
AR092289A1 (es) 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
EP2796451B1 (fr) * 2011-12-20 2018-08-01 Wei Qian Dérivé hétérocyclique de quinazoline substitué par un amido-alkyloxy et son utilisation
CN102643268B (zh) * 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
EP2620869B1 (fr) 2012-01-27 2017-11-01 Optim Corporation Terminal portable, procédé et programme de changement d'interface utilisateur
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
NZ629499A (en) 2012-03-30 2016-05-27 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
WO2013166296A1 (fr) 2012-05-02 2013-11-07 Exelixis, Inc. Double modulateur met-vegf pour traiter des métastases osseuses ostéolytiques
WO2013180128A1 (fr) * 2012-05-28 2013-12-05 協和発酵キリン株式会社 Dérivé de 4-[4-(hétérocyclique aromatique à 5 chaînons carbonyl uréide)phényloxy]quinoléine
CN103509024B (zh) * 2012-06-28 2015-10-28 上海医药工业研究院 嘧啶并苯并氮杂卓类化合物及其作为抗肿瘤药物的应用
CN103626762B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其应用
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
CN103705521A (zh) * 2012-09-28 2014-04-09 韩冰 一类治疗脑梗塞的化合物及其用途
CN102977014B (zh) * 2012-11-05 2015-01-07 沈阳药科大学 新的喹啉类化合物及其用途
CN103804305A (zh) * 2012-11-05 2014-05-21 韩文毅 一类治疗湿疹的化合物及其用途
CN103804382A (zh) * 2012-11-05 2014-05-21 韩文毅 一类治疗湿疹的化合物及其用途
CN103804381A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804290A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804298A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804362A (zh) * 2012-11-12 2014-05-21 韩文毅 一类治疗糖尿病的化合物及其用途
CN103804306A (zh) * 2012-11-12 2014-05-21 韩文毅 一类治疗糖尿病的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN102964308B (zh) * 2012-11-30 2015-03-18 中国药科大学 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN103965104B (zh) * 2013-01-29 2017-09-29 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
WO2014128622A1 (fr) 2013-02-21 2014-08-28 Glaxosmithkline Intellectual Property Development Limited Quinazolines en tant qu'inhibiteurs de kinase
KR20150128863A (ko) * 2013-03-15 2015-11-18 에프. 호프만-라 로슈 아게 RORc 조절제로서 아릴 설파미드 및 설파메이트 유도체
WO2014145693A1 (fr) * 2013-03-15 2014-09-18 Exelixis, Inc. Métabolites de n-[3-fluoro-4-({ 6-(méthyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phényl]-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide
MX366003B (es) 2013-03-15 2019-06-24 Exelixis Inc Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida.
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
BR112015025408A8 (pt) * 2013-04-04 2018-07-10 Exelixis Inc combinações de drogas para tratar câncer
CN104109124B (zh) * 2013-04-19 2016-08-31 正大天晴药业集团股份有限公司 卡博替尼·0.5苹果酸盐的晶体
CN104109128B (zh) * 2013-04-19 2016-10-05 连云港润众制药有限公司 卡博替尼苹果酸盐及其制备方法
AU2014266223B2 (en) 2013-05-14 2020-06-25 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN104370811B (zh) * 2013-08-15 2019-02-12 广东东阳光药业有限公司 一种喹啉化合物的新晶型及其制备方法
PT3039424T (pt) 2013-08-28 2020-09-03 Crown Bioscience Inc Taicang Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
WO2015123639A1 (fr) 2014-02-14 2015-08-20 Exelixis, Inc. Formes solides cristallines du n-{4-[(6,7-diméthoxyquinolin-4-yl)oxy]phényl}-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide, procédés de préparation, et méthodes d'utilisation
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
JP6513076B2 (ja) * 2014-02-28 2019-05-15 国立大学法人東北大学 アミド誘導体
WO2015142928A1 (fr) 2014-03-17 2015-09-24 Exelixis, Inc. Dosage de préparations de cabozantinib
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
HUE054557T2 (hu) 2014-04-25 2021-09-28 Exelixis Inc Eljárás tüdõ adenokarcinóma kezelésére
US9815789B2 (en) 2014-05-23 2017-11-14 Mylan Laboratories, Ltd. Polymorphs of cabozantinib (S)-malate and cabozantinib free base
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
MA40386A (fr) * 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
BR112017002318A2 (pt) 2014-08-05 2018-07-17 Exelixis, Inc. combinações de fármacos para tratar mieloma múltiplo.
EP4089076A1 (fr) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. Dérivé de quinoline à pureté élevée et son procédé de fabrication
US10137107B2 (en) 2014-09-19 2018-11-27 New York Blood Center, Inc. Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV
KR102595599B1 (ko) 2014-12-02 2023-11-02 이그니타, 인코포레이티드 신경모세포종의 치료를 위한 병용
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
RS65049B1 (sr) 2015-02-25 2024-02-29 Eisai R&D Man Co Ltd Metoda za suzbijanje gorčine derivata kinolina
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US10053427B2 (en) 2015-03-25 2018-08-21 Sandoz Ag Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride
CN106279147A (zh) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
SG11201710198YA (en) 2015-06-16 2018-01-30 Eisai R&D Man Co Ltd Anticancer agent
US20170020856A1 (en) * 2015-06-29 2017-01-26 Ontogenesis, Llc N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use
US20180237378A1 (en) * 2015-08-19 2018-08-23 Sandoz Ag Asymmetric Bisamidation of Malonic Ester Derivatives
CN105218445B (zh) * 2015-08-25 2018-05-22 江苏中邦制药有限公司 一种酪氨酸激酶抑制剂Foretinib的制备方法
CN106543143B (zh) * 2015-09-22 2019-03-22 合肥中科普瑞昇生物医药科技有限公司 一类新型的flt3激酶抑制剂及其用途
MX2018007266A (es) 2015-12-18 2018-11-09 Ignyta Inc Combinaciones para el tratamiento del cancer.
CN105541798B (zh) * 2016-02-03 2018-01-23 中国人民解放军第二军医大学 具有抗肿瘤活性的喹啉类多靶点激酶抑制剂及其制备方法
CN107129465B (zh) * 2016-02-26 2020-06-19 中国科学院上海药物研究所 芳基胍类化合物及其制备方法和用途
AU2017244139A1 (en) * 2016-03-31 2018-09-13 Merck Patent Gmbh Compounds for the inhibition of cyclophilins and uses thereof
CA3020749A1 (fr) 2016-04-15 2017-10-19 Exelixis, Inc. Procede de traitement du cancer a cellules renales a l'aide de n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN105906568A (zh) * 2016-04-28 2016-08-31 西安交通大学 一种具有抗肿瘤活性的环丙二酰胺化合物及其制备方法和应用
CN106083715A (zh) * 2016-06-01 2016-11-09 谢阳 一种喹啉、喹唑啉类化合物及其药物组合物和应用
CN106008371A (zh) * 2016-06-24 2016-10-12 谢阳 1-芳基脲基环烷基-1-甲酰胺类化合物及其药物组合物和应用
CN107556238A (zh) * 2016-06-30 2018-01-09 深圳万乐药业有限公司 一种卡博替尼的合成方法
WO2018026877A1 (fr) 2016-08-05 2018-02-08 Calitor Sciences, Llc Méthode de préparation de composés de quinoléine-4-ol substitués
WO2018049329A1 (fr) * 2016-09-12 2018-03-15 Zhuhai Beihai Biotech Co., Ltd. Formulations de cabozantinib
CN110437145A (zh) * 2016-09-13 2019-11-12 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
CA3038500A1 (fr) 2016-09-27 2018-04-05 Andrea B. Apolo Procede de traitement du carcinome urothelial et d'autres malignites genito-urinaires a l'aide de n-(4-(6,7-dimethoxyquinolin-4-yloxy)-phenyl)-n'-(4-fluorophenyl)cyclopropane -1,1 -dicarboxamide
CN109496212B (zh) * 2016-10-18 2020-08-14 北京康辰药业股份有限公司 一种喹啉基取代的羧酸化合物或其药学上可接受的盐、其药物组合物及应用
JP7105774B2 (ja) 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド がん治療のための方法
CN106632028B (zh) * 2016-12-22 2019-01-22 上海再启生物技术有限公司 一种卡博替尼的制备方法
CN108329298A (zh) * 2017-01-17 2018-07-27 南昌弘益药业有限公司 一类喹啉类新化合物制备方法
KR20230169458A (ko) 2017-01-20 2023-12-15 엑셀리시스, 인코포레이티드 암을 치료하기 위한 카보잔티닙 및 아테졸리주맙의 조합
JP6771594B2 (ja) 2017-02-15 2020-10-21 大鵬薬品工業株式会社 医薬組成物
CN108503650B (zh) * 2017-02-27 2021-02-12 北京赛特明强医药科技有限公司 二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用
CN110546147B (zh) * 2017-04-27 2023-05-23 阿斯利康(瑞典)有限公司 苯氧基喹唑啉化合物及其在治疗癌症中的用途
MX2019012505A (es) * 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
WO2018227119A1 (fr) 2017-06-09 2018-12-13 Exelixis, Inc. Formes galéniques liquides destinées à traiter le cancer
JP7159282B2 (ja) * 2017-07-14 2022-10-24 イネイト・テューマー・イミュニティ・インコーポレイテッド Ｎｌｒｐ３モジュレーター
IL271759B2 (en) 2017-07-19 2024-01-01 Ignyta Inc Pharmaceutical preparations that include anthraxtinib
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
PE20210128A1 (es) * 2017-08-31 2021-01-19 Abbvie Inc Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
EP3697390A1 (fr) 2017-10-17 2020-08-26 Ignyta, Inc. Compositions pharmaceutiques et formes galéniques solides
KR20200074164A (ko) 2017-10-20 2020-06-24 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
AU2018360581A1 (en) 2017-10-31 2020-06-11 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
CN109824587A (zh) * 2017-11-23 2019-05-31 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂xjf007及其中间体的制备方法
CN109896997A (zh) * 2017-12-08 2019-06-18 中国药科大学 N－酰基苯胺类c－Met激酶抑制剂的制备方法及其用途
WO2019125798A1 (fr) 2017-12-20 2019-06-27 Angex Pharmaceutical, Inc. Composés de carbamate et d'urée utilisés comme inhibiteurs de multikinases
US20190262330A1 (en) * 2017-12-21 2019-08-29 Exelixis, Inc. Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
AU2019212801B2 (en) * 2018-01-26 2024-07-04 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
JP7480048B2 (ja) * 2018-01-26 2024-05-09 エグゼリクシス， インコーポレイテッド キナーゼ依存的障害を処置するための化合物
MA51672A (fr) * 2018-01-26 2020-12-02 Exelixis Inc Composés destinés au traitement des troubles kinases-dépendants
AU2019216492A1 (en) 2018-02-02 2020-08-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
CN108264482A (zh) * 2018-02-05 2018-07-10 南京法恩化学有限公司 一种卡博替尼的制备方法
KR102433023B1 (ko) 2018-02-11 2022-08-16 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 디옥시노퀴놀린 화합물, 이의 제조방법 및 용도
WO2019180141A1 (fr) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinaisons de rogaratinib
WO2019234761A1 (fr) 2018-06-05 2019-12-12 Natco Pharma Limited Procédé amélioré pour la préparation de cabozantinib et de ses sels pharmaceutiquement acceptables
KR20210042896A (ko) 2018-06-15 2021-04-20 한다 파마슈티칼스, 인코포레이티드 카이네이스 억제제 염 및 이의 조성물
WO2020027723A1 (fr) * 2018-08-01 2020-02-06 Agency For Science, Technology And Research Composés bicycliques utilisés en tant que modulateurs de kinase, procédés et utilisations de ceux-ci
CN110862398B (zh) * 2018-08-27 2021-04-06 北京赛特明强医药科技有限公司 脲取代的芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用
WO2020075196A1 (fr) 2018-10-11 2020-04-16 Cipla Limited Polymorphes de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophényl)cyclopropane-1, 1-dicarboxamide, (s)-malate, leurs procédés de production et leurs utilisations pharmaceutiques
CN111303024B (zh) * 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
PE20211757A1 (es) 2018-12-13 2021-09-07 Exelixis Inc Formas cristalinas y formas de sal de un inhibidor de cinasa
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
WO2020210481A1 (fr) * 2019-04-12 2020-10-15 Nation Health Research Institutes Composés hétérocycliques en tant qu'inhibiteurs de kinase pour des utilisations thérapeutiques
CN111825609A (zh) * 2019-04-22 2020-10-27 北京康辰药业股份有限公司 化合物晶型、其制备方法、药物组合物以及应用
GEP20247655B (en) * 2019-06-03 2024-08-26 Exelixis Inc Crystalline salt forms of kinase inhibitor
CN110117254B (zh) * 2019-06-20 2022-05-13 江苏君若药业有限公司 卡博替尼的制备方法
CN112778217B (zh) * 2019-11-08 2024-01-26 沈阳化工研究院有限公司 一种喹唑啉类化合物及其应用
CN111393363B (zh) * 2020-04-27 2022-12-20 威海海洋生物医药产业技术研究院有限公司 4-苯氧基喹啉并n-磺酰脒类化合物及其制备方法和用途
CN113577066B (zh) * 2020-04-30 2022-12-16 中国科学院上海药物研究所 芳基胍化合物或其药学上可接受的盐的用途
IT202000027678A1 (it) 2020-11-18 2022-05-18 Indena Spa Dispersioni solide amorfe di cabozantinib-(s)-malato e processi per la loro preparazione
WO2022115464A1 (fr) 2020-11-25 2022-06-02 Nanocopoeia, Llc Particules de cabozantinib amorphes et utilisations associées
WO2022130270A1 (fr) * 2020-12-17 2022-06-23 Astrazeneca Ab N-(2-(4-cyanothiazolidin-3-yl)-2-oxoéthyl)-quinoléine-4-carboxamides
EP4313048A1 (fr) * 2021-03-24 2024-02-07 Biocon Limited Procédé de préparation de cabozantinib
CA3237696A1 (fr) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Inhibiteurs du recepteur du facteur de croissance derive des plaquettes (pdgfr) alpha et leurs utilisations
WO2023098853A1 (fr) * 2021-12-03 2023-06-08 湖南湘源美东医药科技有限公司 Cocristal de cabozantinib, son procédé de préparation et son utilisation en tant que médicament ou dans une préparation pharmaceutique
CN114605391B (zh) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用
WO2023165948A1 (fr) 2022-03-01 2023-09-07 Synthon B.V. Sel de cabozantinib à l'acide l (+) tartrique et ses formes solides
WO2023222946A1 (fr) 2022-05-18 2023-11-23 Fermion Oy Procédé de préparation de cabozantinib
WO2023228095A1 (fr) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Schéma posologique d'un conjugué anticorps anti-cdh6-médicament
TW202421146A (zh) 2022-07-08 2024-06-01 瑞典商阿斯特捷利康公司 用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑與ｈｇｆ受體抑制劑的組合
WO2024110606A1 (fr) 2022-11-25 2024-05-30 Synthon B.V. Procédé de préparation de cabozantinib ou de tivozanib
WO2024114710A1 (fr) * 2022-12-01 2024-06-06 江苏奥赛康药业有限公司 Procédé de préparation de cabozantinib et d'un intermédiaire de celui-ci
WO2024163400A1 (fr) * 2023-01-31 2024-08-08 Handa Oncology, Llc Compositions de cabozantinib améliorées et procédés d'utilisation

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US506181A (en) 1893-10-03 Folding crate
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
US5123951A (en) * 1986-03-31 1992-06-23 Rhone-Poulenc Nederland B.V. Synergistic plant growth regulator compositions
JPS646261A (en) * 1987-03-31 1989-01-10 Nisshin Flour Milling Co 4-thioquinazoline derivative, its production and antiulcer agent containing said derivative as active component
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
US5238951A (en) * 1991-02-01 1993-08-24 E. R. Squibb & Sons, Inc. Heterocyclic amido prostaglandin analogs
DE4114733A1 (de) * 1991-05-06 1992-11-12 Huels Chemische Werke Ag Verfahren zur herstellung von substituierten malonesteraniliden und malonsaeure-monoaniliden
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (fr) 1994-11-12 1997-12-01 Zeneca Ltd
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
ES2308962T3 (es) 1995-06-07 2008-12-16 Glaxosmithkline Biologicals S.A. Vacunas que comprenden un conjugado de antigeno polisacarido-proteina transportadora y una proteina transportadora libre.
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
AU5984296A (en) * 1995-06-07 1996-12-30 Sugen, Inc. Quinazolines and pharmaceutical compositions
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AU7340096A (en) * 1995-11-07 1997-05-29 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
KR19990082463A (ko) * 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
DE69734149T2 (de) * 1996-03-15 2006-07-06 Astrazeneca Ab Cinoline derivate und verwendung als heilmittel
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
NZ332119A (en) * 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AR007857A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
CA2263479A1 (fr) 1996-09-25 1998-04-02 Zeneca Limited Derives quinolines inhibant les effets de facteurs de croissance tels que le facteur de croissance endotheliale vasculaire
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0882717B1 (fr) * 1996-10-01 2010-09-08 Kyowa Hakko Kirin Co., Ltd. Composes azotes heterocycliques
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
DE69816080T2 (de) 1997-04-18 2004-04-15 Kirin Beer K.K. Verfahren zur herstellung von chinolinderivaten
WO1998047874A1 (fr) 1997-04-22 1998-10-29 Janssen Pharmaceutica N.V. Quino- et quinazolines antagonistes crf
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
JP4194678B2 (ja) * 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
EP1082311A1 (fr) * 1998-05-28 2001-03-14 Parker Hughes Institute Utilisation des quinazolines pour le traitement de tumeurs cerebrales
ATE459616T1 (de) * 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
JP2002523403A (ja) * 1998-08-21 2002-07-30 パーカー ヒューズ インスティテュート キナゾリン誘導体
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP5170486B2 (ja) 1998-09-10 2013-03-27 バイオイコール ア−ゲー 局所適用性産物
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
EA004436B1 (ru) 1998-09-29 2004-04-29 Уайт Холдингз Корпорейшн Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
AU761552B2 (en) * 1998-10-01 2003-06-05 Astrazeneca Ab Chemical compounds
ATE294796T1 (de) 1998-10-08 2005-05-15 Astrazeneca Ab Chinazolin derivate
KR20010080491A (ko) * 1998-11-19 2001-08-22 로즈 암스트롱, 크리스틴 에이. 트러트웨인 티로신 키나제의 비가역적 저해제인ｎ-[4-(3-클로로-4-플루오로-페닐아미노)-7-(3-모르폴린-4-일-프로폭시)-퀴나졸린-6-일]-아크릴아미드
AU771504B2 (en) * 1999-01-22 2004-03-25 Kyowa Hakko Kirin Co., Ltd. Quinoline derivatives and quinazoline derivatives
EP1553097B1 (fr) 1999-02-10 2010-09-29 AstraZeneca AB Derives de quinazoline utilises comme inhibiteurs de l'angiogenese et produits intermediares
GB9904103D0 (en) * 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2000056338A1 (fr) 1999-03-19 2000-09-28 Parker Hughes Institute Formulations de quinazoline et leur utilisation therapeutique
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
GB9910580D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
EA004981B1 (ru) * 1999-06-21 2004-10-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
ATE449083T1 (de) * 1999-09-21 2009-12-15 Astrazeneca Ab Chinazolin-derivate und ihre verwendung als arzneimittel
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
AU4903201A (en) * 1999-11-30 2001-07-03 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
US20020002169A1 (en) * 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
WO2001047890A1 (fr) * 1999-12-24 2001-07-05 Kirin Beer Kabushiki Kaisha Quinoline, derives de la quinazoline et medicaments contenant ces substances
US6525046B1 (en) * 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6977259B2 (en) * 2000-01-28 2005-12-20 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
US6664390B2 (en) 2000-02-02 2003-12-16 Warner-Lambert Company Llc Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
SK12712002A3 (sk) * 2000-02-07 2003-02-04 Abbott Gmbh & Co. Kg Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
IL151249A0 (en) 2000-03-13 2003-04-10 American Cyanamid Co Use of cyanoquinolines for treating or inhibiting colonic polyps
US6608048B2 (en) * 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US6627634B2 (en) * 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
YU95102A (sh) * 2000-06-22 2005-11-28 Pfizer Products Inc. Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
EP1174118A1 (fr) 2000-06-28 2002-01-23 Cognis France S.A. Utilisation de l'inuline et de dérivés de celui-ci
WO2002000649A1 (fr) 2000-06-28 2002-01-03 Astrazeneca Ab Derives de la quinazoline substitues et leur utilisation comme inhibiteurs
FR2811658B1 (fr) 2000-07-17 2004-07-02 Cfpi Nufarm Reacteur biologique a lit fixe immerge et procede de traitement d'effluents liquides
JP2002030083A (ja) * 2000-07-18 2002-01-29 Kirin Brewery Co Ltd Ｎ−（２−クロロ−４−｛［６−メトキシ−７−（３−ピリジルメトキシ）−４−キノリル］オキシ｝フェニル）−ｎ’−プロピルウレアの二塩酸塩
CA2417500C (fr) * 2000-07-28 2008-11-18 Georgetown University Medical Center Inhibiteur de l'erbb-2 kinase selectif de petites molecules
RU2267489C2 (ru) 2000-08-21 2006-01-10 Астразенека Аб Производные хиназолина, способ их получения и фармацевтическая композиция
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US6740651B2 (en) * 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6403580B1 (en) * 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6617329B2 (en) * 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
JP2004511480A (ja) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ キナゾリン誘導体
JP2004511479A (ja) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ キナゾリン誘導体
ES2282299T3 (es) * 2000-10-20 2007-10-16 EISAI R&D MANAGEMENT CO., LTD. Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
JP2004512335A (ja) 2000-10-25 2004-04-22 アストラゼネカ　アクチボラグ キナゾリン誘導体
EP1337524A1 (fr) 2000-11-02 2003-08-27 AstraZeneca AB Quinolines substituees comme agents antitumoraux
EP1340748B1 (fr) 2000-11-02 2008-01-16 Nippon Shinyaku Co., Ltd. Derives quinazoline et medicaments
US7253184B2 (en) 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
ES2312557T3 (es) 2001-04-19 2009-03-01 Astrazeneca Ab Derivados de quinazolina.
CA2445333C (fr) * 2001-04-27 2011-03-22 Kirin Beer Kabushiki Kaisha Derives de quinoline et de quinazoline ayant un groupe azolyle
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
WO2002092579A1 (fr) 2001-05-14 2002-11-21 Astrazeneca Ab Derives de 4-anilinoquinazoline
WO2002092577A1 (fr) 2001-05-14 2002-11-21 Astrazeneca Ab Derives quinazoliniques
WO2002092578A1 (fr) 2001-05-14 2002-11-21 Astrazeneca Ab Derives de quinazoline
US6734303B2 (en) * 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
DE10125432A1 (de) * 2001-05-25 2002-11-28 Bayer Ag Substituierte Benzoylketone
EP1408980A4 (fr) 2001-06-21 2004-10-20 Ariad Pharma Inc Nouvelles quinazolines et leur utilisation
ATE443047T1 (de) 2001-06-22 2009-10-15 Kirin Pharma Kk Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus- proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
GB0118752D0 (en) * 2001-08-01 2001-09-26 Pfizer Ltd Process for the production of quinazolines
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20030066060A1 (en) 2001-09-28 2003-04-03 Ford Richard L. Cross profile guided optimization of program execution
EP1447405A4 (fr) 2001-10-17 2005-01-12 Kirin Brewery Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
AU2002361577A1 (en) 2001-10-30 2003-05-12 Merck And Co., Inc. Tyrosine kinase inhibitors
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
AR037438A1 (es) * 2001-11-27 2004-11-10 Wyeth Corp 3-cianoquinolinas como inhibidores de egf-r y her2 quinasas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
AU2002347336A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
AU2002347359A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
BR0214499A (pt) * 2001-12-12 2005-05-10 Pfizer Prod Inc Derivados de quinazolina para o tratamento do crescimento anormal das células
AU2002366581A1 (en) 2001-12-12 2003-06-23 Pfizer Products Inc. Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
AU2002361846A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
BRPI0215312B8 (pt) 2001-12-24 2021-05-25 Astrazeneca Ab composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
EP2181996A1 (fr) 2002-01-29 2010-05-05 Glaxo Group Limited Derivées d'aminopieridines
EP1470131A2 (fr) 2002-01-29 2004-10-27 Glaxo Group Limited Composes aminopiperidine, leur procede de preparation et compositions pharmaceutiques les contenant
ES2381781T3 (es) 2002-02-01 2012-05-31 Astrazeneca Ab Compuestos de quinazolina
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US20050049267A1 (en) * 2002-03-01 2005-03-03 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
DE10217689A1 (de) 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
JPWO2003093238A1 (ja) * 2002-05-01 2005-09-08 麒麟麦酒株式会社 マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
JPWO2004018430A1 (ja) * 2002-08-23 2005-12-08 麒麟麦酒株式会社 ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
ES2294317T3 (es) 2002-10-21 2008-04-01 Kirin Pharma Kabushiki Kaisha Sal de n-(2-cloro-4-((6,7-dimetoxi-4-quinolil)oxi)fenil)-n'-(5-metil-3-isoxazolil)urea de forma cristalina.
WO2004039782A1 (fr) * 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Derives de quinoline et de quinazoline inhibant l'autophosphorylation de flt3 et compositions medicales les contenant
JP4593464B2 (ja) 2002-11-04 2010-12-08 アストラゼネカ アクチボラグ Ｓｒｃチロシンキナーゼ阻害剤としてのキナゾリン誘導体
CN1726205A (zh) 2002-12-13 2006-01-25 神经能质公司 作为辣椒素受体调节剂的2－取代的喹唑啉－4－基胺类似物
AU2003303045A1 (en) 2002-12-18 2004-07-09 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
EP1575591A4 (fr) 2002-12-23 2007-09-12 Ariad Pharma Inc Heterocycles et leurs utilisations
AU2003292838A1 (en) * 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration
US8176532B1 (en) * 2003-03-17 2012-05-08 Sprint Communications Company L.P. Secure access point for scada devices
KR100559180B1 (ko) * 2003-05-20 2006-03-14 김민서 조건부 거래에 따른 전자결제 방법 및 전자결제 서버
WO2005003140A1 (fr) 2003-07-02 2005-01-13 Pharmacia & Upjohn Company Llc 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides utilises comme agents antiviraux
CA2531485C (fr) 2003-07-07 2013-03-26 Merck Patent Gmbh Derives de malonamide
CA2537812C (fr) * 2003-09-26 2013-01-22 Exelixis, Inc. Modulateurs de c-met et procede d'utilisation
WO2005073224A2 (fr) 2004-01-23 2005-08-11 Amgen Inc Composes et methodes d'utilisation de ces derniers
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
AU2005270068B2 (en) * 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
EP1874759A4 (fr) * 2005-04-06 2009-07-15 Exelixis Inc Modulateurs c-met modulators et procedes d utilisation
US7594258B2 (en) * 2005-06-27 2009-09-22 Yahoo! Inc. Access control systems and methods using visibility tokens with automatic propagation
WO2008035209A2 (fr) * 2006-05-30 2008-03-27 Methylgene Inc. Inhibiteurs de l'activité tyrosine kinase
MX2011003363A (es) 2008-10-01 2011-04-27 Ludwig Inst Cancer Res Metodos para el tratamiento de cancer.
CN102239148A (zh) * 2008-12-04 2011-11-09 埃克塞里艾克西斯公司 喹啉衍生物的制备方法
KR20200137052A (ko) * 2009-01-16 2020-12-08 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
WO2011009095A1 (fr) * 2009-07-17 2011-01-20 Exelixis, Inc. Formes cristallines du n‑[3‑fluoro-4-({méthyloxy)-7-[(3-morpholin-4-yl- propyl)oxy]quinoléin-4-yl}oxy)phényl]-n'-(4-fluorophényl)cyclopropane- 1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2475390A4 (fr) 2009-09-09 2014-01-01 Quintiles Transnat Corp Méthodes et compositions pour le traitement de maladies ou troubles à médiation par le récepteur tyrosine kinase
JP5461213B2 (ja) 2010-01-29 2014-04-02 三洋電機株式会社 空気調和装置の室外ユニット
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
US20120252840A1 (en) * 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer

Also Published As

Publication number Publication date
JP5325173B2 (ja) 2013-10-23
SI2210607T1 (sl) 2011-11-30
EP1673085A4 (fr) 2008-12-10
JP2007506777A (ja) 2007-03-22
EP2213661A1 (fr) 2010-08-04
EP3329918B1 (fr) 2022-05-25
AU2010204461B2 (en) 2013-06-20
HRP20110707T1 (hr) 2011-10-31
JP2017160270A (ja) 2017-09-14
SI2392564T1 (sl) 2014-02-28
HK1141799A1 (en) 2010-11-19
DK2210607T3 (da) 2011-12-12
ES2369652T3 (es) 2011-12-02
FR14C0067I1 (fr) 2014-10-17
DK2213661T3 (da) 2011-09-19
CY2014037I1 (el) 2015-11-04
EP2210607A1 (fr) 2010-07-28
EP2392564B1 (fr) 2013-10-23
HRP20110810T1 (hr) 2011-12-31
EP2612853A1 (fr) 2013-07-10
JP2014055190A (ja) 2014-03-27
CY1111956T1 (el) 2015-11-04
CY2014037I2 (el) 2019-07-10
FR14C0067I2 (fr) 2015-11-20
SI2213661T1 (sl) 2011-11-30
US20120184523A1 (en) 2012-07-19
HK1164313A1 (en) 2012-09-21
US8476298B2 (en) 2013-07-02
CA2744997A1 (fr) 2005-04-07
US20110077233A1 (en) 2011-03-31
US20090170896A1 (en) 2009-07-02
AU2010204459A1 (en) 2010-08-19
WO2005030140A3 (fr) 2005-05-19
ES2925655T3 (es) 2022-10-19
US20140155396A1 (en) 2014-06-05
AU2004275842B2 (en) 2010-09-02
DK2392564T3 (da) 2014-01-13
JP2015131859A (ja) 2015-07-23
US20070244116A1 (en) 2007-10-18
JP2011042686A (ja) 2011-03-03
ATE532782T1 (de) 2011-11-15
EP1673085A2 (fr) 2006-06-28
PT2213661E (pt) 2011-12-15
ATE517091T1 (de) 2011-08-15
AU2010204461A1 (en) 2010-08-19
US8178532B2 (en) 2012-05-15
HUS1400052I1 (hu) 2022-02-28
AU2010204459B2 (en) 2013-06-20
CY1112056T1 (el) 2015-11-04
EP2392565B1 (fr) 2014-03-19
HK1143068A1 (en) 2010-12-24
US20090105299A1 (en) 2009-04-23
US20130252940A1 (en) 2013-09-26
US7579473B2 (en) 2009-08-25
DK2392565T3 (da) 2014-05-05
JP5185331B2 (ja) 2013-04-17
EP2409704A3 (fr) 2013-02-13
EP2609919A3 (fr) 2014-02-26
ES2651730T3 (es) 2018-01-29
EP2392565A1 (fr) 2011-12-07
JP2014055191A (ja) 2014-03-27
JP2019070015A (ja) 2019-05-09
JP2010265302A (ja) 2010-11-25
EP3329918A3 (fr) 2018-08-15
EP2213661B1 (fr) 2011-07-20
US20070225307A1 (en) 2007-09-27
JP2021050233A (ja) 2021-04-01
HRP20140563T1 (hr) 2014-07-18
PL2392565T3 (pl) 2014-08-29
AU2004275842A1 (en) 2005-04-07
SI2392565T1 (sl) 2014-05-30
US8067436B2 (en) 2011-11-29
JP2010235632A (ja) 2010-10-21
CA2537812C (fr) 2013-01-22
JP2010280674A (ja) 2010-12-16
JP5694501B2 (ja) 2015-04-01
US20210253530A9 (en) 2021-08-19
NL300678I2 (fr) 2017-01-31
EP2409704A2 (fr) 2012-01-25
US20070054928A1 (en) 2007-03-08
EP2409704B1 (fr) 2017-09-20
JP4638436B2 (ja) 2011-02-23
JP5185332B2 (ja) 2013-04-17
WO2005030140A2 (fr) 2005-04-07
EP1673085B1 (fr) 2011-11-09
EP2609919A2 (fr) 2013-07-03
ES2436888T3 (es) 2014-01-07
US20140155378A9 (en) 2014-06-05
PT2210607E (pt) 2012-01-31
ATE520403T1 (de) 2011-09-15
CA2537812A1 (fr) 2005-04-07
EP3329918A2 (fr) 2018-06-06
US20150376133A1 (en) 2015-12-31
EP2392564A1 (fr) 2011-12-07
JP5325172B2 (ja) 2013-10-23
JP2010235631A (ja) 2010-10-21
US20170355678A1 (en) 2017-12-14
JP2024023447A (ja) 2024-02-21
EP2210607B1 (fr) 2011-08-17
US9174947B2 (en) 2015-11-03
HK1164312A1 (en) 2012-09-21
US20200331860A1 (en) 2020-10-22
ES2371383T3 (es) 2011-12-30
HK1256476A1 (zh) 2019-09-27
JP2014074059A (ja) 2014-04-24
PL2213661T3 (pl) 2011-12-30
HRP20140012T1 (hr) 2014-02-14
PL2210607T3 (pl) 2012-01-31
US11124482B2 (en) 2021-09-21
ES2466818T3 (es) 2014-06-11
US20160185725A1 (en) 2016-06-30
US20120022065A1 (en) 2012-01-26
US8497284B2 (en) 2013-07-30
LU92508I2 (fr) 2015-11-02

Similar Documents

Publication Publication Date Title
BE2014C055I2 (fr)
BE2014C027I2 (fr)
BE2014C003I2 (fr)
BE2013C075I2 (fr)
BE2013C069I2 (fr)
BE2013C067I2 (fr)
JP2004071573A5 (fr)
JP2004005637A5 (fr)
JP2004220424A5 (fr)
IN2006CH01650A (fr)
BE2015C005I2 (fr)
JP2004000632A5 (fr)
JP2004107094A5 (fr)
JP2004001473A5 (fr)
JP2003263271A5 (fr)
JP2004000194A5 (fr)
JP2004164817A5 (fr)
AU2003207750A1 (fr)
AU2002362930A1 (fr)
AU2002324323A1 (fr)
AU2002322913A1 (fr)
AU2002321535A1 (fr)
AU2002327736A1 (fr)
AU2002318342A1 (fr)
AU2002331433A1 (fr)